投资机构Leerink Partners宣布将癌症检测公司NeoGenomics的股票评级从"与大市持平"上调至"跑赢大盘",同时将其目标股价从12美元大幅提升至25美元,显示出对该公司在肿瘤基因检测领域发展前景的强烈信心。
此次评级调整反映了分析师对NeoGenomics业务转型和增长潜力的重新评估。目标价的大幅上调表明Leerink Partners认为该公司当前股价尚未充分反映其未来价值,预计其股价将有显著上行空间。
投资机构Leerink Partners宣布将癌症检测公司NeoGenomics的股票评级从"与大市持平"上调至"跑赢大盘",同时将其目标股价从12美元大幅提升至25美元,显示出对该公司在肿瘤基因检测领域发展前景的强烈信心。
此次评级调整反映了分析师对NeoGenomics业务转型和增长潜力的重新评估。目标价的大幅上调表明Leerink Partners认为该公司当前股价尚未充分反映其未来价值,预计其股价将有显著上行空间。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.